HCQ 200 KYMYK QINMAX PLAQUIN-H PLAYQUIN-H HYQUINE

Dose: 5.714 mg/kg
Single Dose: 5.7 (5.714)
Frequency: 8 hourly
Route: PO
Instructions: Maintenance, As Required

Dose: 5 mg/kg
Single Dose: 5 (5)
Frequency: As recommended.
Route: PO
Instructions: Once weekly

. It is of Synthetic origin and belongs to Chloroquine. It belongs to Antiplasmodial pharmacological group on the basis of mechanism of action and also classified in Antimalarial Agent pharmacological group.The Molecular Weight of Hydroxychloroquine (Sulphate) is 433.90.

Hydroxychloroquine (Sulphate) is contraindicated in conditions like Psoriasis,Renal diseases,Hepatic disease,Retinopathy,G6pd deficiency,GI diseases,Neurological disorders,Blood disorders,Porphyria cutanea tarda.

The severe or irreversible adverse effects of Hydroxychloroquine (Sulphate), which give rise to further complications include Retinotoxicity.Hydroxychloroquine (Sulphate) produces potentially life-threatening effects which include Cardiotoxicity. which are responsible for the discontinuation of Hydroxychloroquine (Sulphate) therapy.The signs and symptoms that are produced after the acute overdosage of Hydroxychloroquine (Sulphate) include Death, Convulsions, Headache, Cardiopulmonary arrest, Cardiovascular collapse, Visual distrubances.The symptomatic adverse reactions produced by Hydroxychloroquine (Sulphate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Ataxia, Nausea, Vomiting, Alopecia, Anorexia, Diarrhea, Skin reactions, Abdominal cramps, Nervousness, Tinnitus, VertigoX, Psychosis, Bleaching of hair, Nightmares, Muscular weakness, Emotional upsets, Nerve deafness, Alopecia, nervousness, Nervousness, Ataxia.

Hydroxychloroquine (Sulphate) is primarily indicated in conditions like Adjunctive treatment of cortical myoclonus, Dermatological diseases, Discoid and systemic lupus erythematosus, Juvenile chronic arthritis, Malaria, Malaria prophylaxis, Premenstrual syndrome, Prophylaxis of bipolar disorder, Prostate cancer (metastatic), flare with initial gonadorelin therapy, Rheumatoid arthritis, Systemic and discoid lupus erythematosus.

Hydroxychloroquine (Sulphate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAluminium Hydroxide and OxideChloroquineCimetidine (HCl)DigoxinHydroxychloroquine may increase the serum concentration of Digoxin.ModerateMonitor for increased serum concentrations/toxic effects of Digoxin if Hydroxychloroquine is initiated/dose increased, or decreased serum concentrations/effects if Hydroxychloroquine is discontinued/dose decreased.Severity Moderate (Sequence Important)NeostigminePenicillaminePyridostigmine (Br)Pyridostigmine (Br)Rivastigmine These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Store Below 40°C. Protect from Moisture and Heat.

Hydroxychloroquine should be used with caution in patients with kidney or liver disease, alcoholism or metabolic acidosis. Perform periodic blood count during prolong therapy, if severe blood disorder appears, discontinue therapy. It should be used with caution in patients with glucose 6 phosphate (G-6-PD) deficiency.Avoid in brest-feeding becouse of risk of toxicity in infants.